Carl Schaper

Comparison of PAM50 Risk of Recurrence Score With Onco<i>type</i> DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

Mitch Dowsett, Ivana Šestak, Elena López‐Knowles et al. · Journal of Clinical Oncology · 2013 · 636 citations · Full text

Medicine, Oncology, Breast Oncology +16

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

Brett Wallden, James J. Storhoff, Torsten O. Nielsen et al. · BMC Medical Genomics · 2015 · 560 citations · Full text

Medicine, Bioinformatics, Oncology +17

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

Michael Gnant, Martin Filipits, Richard Greil et al. · Annals of Oncology · 2013 · 399 citations · Full text

Medicine, Oncology, Breast Oncology +13

Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens

Torsten O. Nielsen, Brett Wallden, Carl Schaper et al. · BMC Cancer · 2014 · 309 citations · Full text

Medicine, Molecular Biology, Oncology +17

Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score

Ivana Šestak, Jack Cuzick, Mitch Dowsett et al. · Journal of Clinical Oncology · 2014 · 247 citations · Full text

Medicine, Endocrinology, Oncology +17